Co-Diagnostics Inc
For the period ended Jun 30, 2024. Filed Aug 8, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 8, 2024
CODX$0.32+24.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
| Three Months Ended June 30, | Six Months Ended June 30, | |||
|---|---|---|---|---|
| 2024 | 2023 | 2024 | 2023 | |
| Product revenue | $161,102 | $197,806 | $413,847 | $799,763 |
| Grant revenue | 2,495,738 | - | 2,710,847 | - |
| Total revenue | 2,656,840 | 197,806 | 3,124,694 | 799,763 |
| Cost of revenue | 212,148 | 459,095 | 446,653 | 961,336 |
| Gross profit | 2,444,692 | (261,289) | 2,678,041 | (161,573) |
| Operating expenses | ||||
| Sales and marketing | 1,041,243 | 1,732,966 | 2,604,925 | 3,439,297 |
| General and administrative | 3,132,385 | 3,713,895 | 6,051,188 | 6,727,860 |
| Research and development | 5,612,691 | 5,981,043 | 11,292,369 | 10,995,103 |
| Depreciation and amortization | 338,335 | 305,246 | 668,908 | 621,256 |
| Total operating expenses | 10,124,654 | 11,733,150 | 20,617,390 | 21,783,516 |
| Loss from operations | (7,679,962) | (11,994,439) | (17,939,349) | (21,945,089) |
| Other income, net | ||||
| Interest income | 342,188 | 191,892 | 704,921 | 394,264 |
| Realized gain on investments | 74,165 | 411,190 | 302,235 | 829,272 |
| Gain on disposition of assets | 3,500 | - | 3,500 | - |
| Gain (loss) on remeasurement of acquisition contingencies | (244,116) | 359,405 | 206,144 | 1,397,077 |
| Gain (loss) on equity method investment in joint venture | (74,503) | (125,193) | (145,458) | 152,129 |
| Total other income, net | 101,234 | 837,294 | 1,071,342 | 2,772,742 |
| Loss before income taxes | (7,578,728) | (11,157,145) | (16,868,007) | (19,172,347) |
| Income tax provision (benefit) | 20,590 | (2,238,320) | 43,354 | (4,498,131) |
| Net loss | $(7,599,318) | $(8,918,825) | $(16,911,361) | $(14,674,216) |
| Other comprehensive loss | ||||
| Change in net unrealized gains on marketable securities, net of tax | 144,653 | 107,366 | 224,508 | 285,987 |
| Total other comprehensive income | $144,653 | $107,366 | $224,508 | $285,987 |
| Comprehensive loss | $(7,454,665) | $(8,811,459) | $(16,686,853) | $(14,388,229) |
| Loss per common share: | ||||
| Basic and Diluted | $(0.25) | $(0.31) | $(0.56) | $(0.50) |
| Weighted average shares outstanding: | ||||
| Basic and Diluted | 30,124,696 | 29,088,159 | 29,983,785 | 29,284,175 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.